In a retrospective analysis of 206 EORTC/NCIC trial patients with MGMT-unmethylated tumours (n = 114), adding temozolomide to radiation therapy resulted in a non-significant survival advantage (two-year survival 15 versus 2%; median overall survival 12.7 versus 11.8 months, HR 0.69, 95% CI 0.47-1.02) (16). This evidence concerns the gene MGMT and neoplasm.